Apellis Pharmaceuticals (APLS)

APLS Complement Inhibitors

BiotechSign Signal Grade

C
Signal Grade
50.2/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Publications
100
Dilution Risk
25
Clinical Activity
88
Short Interest
50

Pipeline Overview

Therapeutic Focus
Complement Inhibitorssrc

Clinical Trial Activity

6
Clinical Trials
(ClinicalTrials.gov aggregate)
3 Phase 2, 2 Phase 3
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Dilution Risk

LOW DILUTION RISK
15.0 months
Cash Runway Estimate
25/100
Dilution Score
15Warrant Risk
15Convertible Risk
20Offering Ability

Dilution score: 25/100 (LOW), 15.0 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

12.92%
Float Shorted
3.1
Days to Cover
MODERATE
Squeeze Risk
-24.5%
SI Change
DECREASING
Trend
10,752,810
Shares Short

Short interest: 12.92% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Apellis Pharmaceuticals.

Full APLS Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.